Home › Trials › NCT04282083

Creating a national database for patients with gastro-entero pancreatic neuroendocrine tumors in Italy

ITANET -Registry: Multicentric Collection of Cases on Neuroendocrin Gastro-Entero-Pancreatic Tumors (Title in Local Language: ITANET -Registry: Raccolta Multicentrica Dei Casi di Tumore Neuroendocrino Gastro-Entero-Pancreatico)

Observational Italian Association Neuroendocrine Tumors · NCT04282083

This study is creating a national database in Italy to collect information on the diagnosis and treatment of patients with gastro-entero pancreatic neuroendocrine tumors to improve care and follow-up.

Quick facts

Study typeObservational
Enrollment3600 (estimated)
Ages18 Years and up
SexAll
SponsorItalian Association Neuroendocrine Tumors Research network
Locations37 sites (Rozzano, Milan and 36 other locations)
Trial IDNCT04282083 on ClinicalTrials.gov

What this trial studies

This observational study aims to establish a comprehensive Italian database for collecting data on the diagnostic approaches, therapies, and follow-up of patients diagnosed with gastro-entero pancreatic neuroendocrine tumors (GEP-NETs). The project will transfer previously collected data from the ENETS database and continue to gather new data from approximately 200 patients across various participating sites in Italy. Each patient will be pseudonymously identified, and data will be collected both prospectively for new diagnoses and retrospectively for follow-up visits. The study emphasizes patient rights and data management through a structured protocol.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older with a confirmed diagnosis of GEP-NET.

Not a fit: Patients with tumors originating from areas other than the digestive apparatus will not benefit from this study.

Why it matters

Potential benefit: If successful, this initiative could enhance the understanding and treatment of GEP-NETs by providing valuable clinical data.

How similar studies have performed: While this approach builds on previous data collection efforts, it represents a continuation rather than a novel or untested methodology.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* age\> or = 18 years;
* histologically/cytologically proved diagnosis of NET OR diagnosis supported by a PET Gallium 68 positivity and by at least a contrastografic imaging of second level (CT scan or NMR);
* Diagnosis of GEP-NET not antecedent 1 year since the Informed Consent signature;
* Grading G1, G2, G3 according to the classification WHO 2019;
* Tumor origin in digestive apparatus (GEP NETs) or tumor of unknown origin;
* Signed Informed consent.

Exclusion Criteria:

* Known tumor origin different from digestive apparatus (GEP NETs);
* no evidence of histologically/cytologically proved diagnosis of NET OR diagnosis supported by a PET Gallium 68 positivity and by at least a contrastografic imaging of second level (CT scan or NMR);
* Diagnosis of GEP-NET antecedent 1 year since the Informed Consent signature.

Where this trial is running

Rozzano, Milan and 36 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Gastro-entero Pancreatic Neuroendocrine TumorsGEP-NETs
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.